In patients with low-risk prostate cancer, HIFU monotherapy resulted in comparable immediate cancer control with other modalities. Particularly, focal therapy might offer a feasible minimally invasive therapeutic option, which maintained serum testosterone level. To our knowledge, this is the first report that whole, but not focal, therapy affects the serum testosterone level.

No abstract

No abstract

Introduction Erectile and endothelial dysfunction are common pathologies of multiple cardiovascular risk factors and are considered longitudinal predictors of cardiovascular events. Oxidative stress and decreases in testosterone levels play an important role in the pathogenesis of endothelial dysfunction. Aim We sought to determine whether the severity of erectile dysfunction (ED) was associated with individual levels of testosterone and oxidative stress, and whether treatment with a phosphodiesterase type 5 inhibitor could reduce oxidative stress and increase testosterone availability. Methods We evaluated the association of salivary 8-hydroxy-2′-deoxyguanosine (8-OHdG), salivary testosterone, International Index of Erectile Function-erectile function domain (IIEF-EF) scores, and Medical Outcome Study (MOS) 36-item Short-Form Healthy Survey (SF-36) questionnaires in 128 middle-aged male volunteers. We investigated the changes in testosterone levels, salivary 8-OHdG levels, IIEF-EF scores, and SF-36 scores in 20 ED patients (according to the IIEF-EF) who took 50 mg of sildenafil once a week for 6 months. Main Outcome Measures IIEF-EF scores were used to assess ED severity. Antioxidant status was defined by salivary 8-OHdG. Salivary testosterone was used to evaluate serum bioavailable testosterone availability. Results Salivary 8-OHdG (OR=9.88, 95% CI: 1.52–64.10), salivary testosterone (Odds ratio [OR]=0.96, 95% CI: 0.93–0.98), and vitality on the SF-36, version 2 (SF-36 v2) (OR=0.92, 95%CI: 0.84–0.98) were significantly associated with the severity of ED in healthy volunteers. Treatment with sildenafil for 6 months significantly increased the total serum testosterone (426.4 ± 174.8 vs. 569.6 ± 146.1 ng/dL, P =0.021) and salivary testosterone levels (56.1 ± 22.3 vs. 110.0 ± 48.4 pg/mL, P <0.001), whereas it decreased salivary 8-OHdG levels (2.30 ± 0.23 vs. 0.90 ± 0.05 ng/mL, P =0.0046). Conclusions Salivary 8-OHdG is a useful biomarker for predicting severe ED and hypogonadism in middle-aged men. Once-a-week treatment with sildenafil can have beneficial effects on men's health by decreasing oxidative stress and increasing testosterone levels.

No abstract